Novel Drug Delivery Systems in Cancer Therapy Market Analysis By Product (Nanoparticles and Embolization Particles), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2018 - 2025

Report Overview

The global novel drug delivery systems in cancer therapy market size was valued at USD 4.31 billion in 2016 and is projected to grow at a CAGR of 22.9% during the forecast period. Worldwide increasing incidence of cancer, availability of research funding, increase in awareness about alternative methods for treatment, and favorable reimbursement scenarios in developed nations are some of the key drivers of this market. In addition, use of nanoparticles to treat cancers is expected to boost market growth.

Key players in the market are investing in R&D for novel drug delivery systems. For instance, Celgene Corporation’s R&D expenditures increased from USD 3,697.3 million in 2015 to USD 4,470.1 million in 2016. This increase was directed toward expanding product portfolio and obtaining regulatory approvals for new products. 

However, lack of awareness about alternative therapies and inadequate funds for development of novel drug delivery systems are expected to impede the growth of the novel drug delivery systems in cancer therapy market during the forecast period. Cancer research projects require huge investment and funding. Although developed nations like the U.S., U.K., and Germany have many organizations that fund new technologies, research projects in countries like Brazil, Mexico, and India are not funded adequately. In addition, awareness about new and alternative treatments is very low in these countries.

Product Insights

Based on the type of novel drug delivery systems, the market is segmented into nanoparticles and embolization particles. Nanoparticles are further segmented into liposomes, polymers, micelles, and other nanoparticles. In 2016, the nanoparticles segment held the largest market share by product and is expected to continue its dominance over the novel drug delivery systems in cancer therapy market throughout the forecast period.

Nanoparticles as novel drug delivery systems are a unique approach in cancer treatment. They encapsulate the drugs and protect them against chemical and enzymatic degradation. Nanoparticles in drug delivery provide long circulation half-lives, help in reducing side effects, and improve pharmacokinetics. These particles also offer enhanced permeability, which allows the efficient delivery of drugs to cancer tissues. Nanoparticles as novel drug delivery systems are thus considered a promising approach to replace traditional chemotherapy, a treatment that poses a serious risk to healthy tissues.

Nanoparticle delivery systems such as liposomes and micelles are often used to increase drug efficacy and DNA delivery and targeting. Continuous improvements in the therapeutic properties of drugs have increased the demand for novel drug delivery systems. In 2016, liposomes held the largest share in the nanoparticles segment, by type. This sub-segment is also expected to grow at the highest rate during the forecast period.

Tumor embolization is a process of blocking blood vessels that supply oxygen and blood to tumors. The embolization particles segment is further categorized into PVA particles, drug-eluting beads, liquid emboli, and other embolization particles. These particles are injected into small vessels supplying blood to cancer cells. This procedure allows for easy surgical resection of cancer cells, resulting from reduced blood loss.

Regional Insights

North America dominated the market in 2016 with a revenue share of around 36.8%. Key factors contributing to the growth of this market include rise in the number of research activities for new therapies, increase in budget for novel drug discovery, growing awareness due to marketing and promotional activities of manufacturers, and increasing incidence of cancer. In addition, FDA approvals for commercial availability of NDDS and rise in number of clinical trials for this therapy are expected to boost market growth in this region.

The Asia Pacific market for novel drug delivery systems in cancer therapy is anticipated to grow at the fastest rate during the forecast period. This can be attributed to rising incidence of cancer in China and Japan, increase in geriatric population in Japan, collaborations between U.S. and China to strengthen cancer research, and rise in awareness about new therapies in Asia Pacific. In addition, increase in research activities in Asia Pacific countries is expected to boost market growth during the forecast period.

Europe held the second-largest share in this market in 2016. The European market is expected to grow significantly owing to presence of a large number of cancer patients, rise in research funding for cancer therapies, increase in awareness about novel therapies among cancer patients, and high healthcare expenditure in the region.

Key Companies & Market Share Insights

Some of the key players operating in the market for novel drug delivery systems in cancer therapy are Teva Pharmaceutical Industries Ltd.; Johnson & Johnson Services, Inc.; GALEN; Merrimack Pharmaceuticals, Inc.; Shire; Samyang Biopharmaceuticals Corporation; Celgene Corporation; Spectrum Pharmaceuticals, Inc.; and BTG. Frequent product launches, geographic expansions, and distribution agreements to increase customer base are some of the key strategies players are undertaking to increase their share.

Novel Drug Delivery Systems In Cancer Therapy Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the novel drug delivery systems (NDDS) in cancer therapy market on the basis of product and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Nanoparticles

    • Liposomes

    • Polymers

    • Micelles

    • Other nanoparticles

  • Embolization particles

    • PVA particles

    • Drug-eluting beads

    • Liquid emboli

    • Other embolization particles

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa